 |
市場調查報告書
商品編碼
1741274
整合酶抑制劑市場按藥物、給藥途徑、分銷管道和地區分類Integrase Inhibitors Market, By Drug, By Route of Administration, By Distribution Channel, By Geography |
||||||
整合酶抑制劑市場規模預計在 2025 年為 164.3 億美元，預計到 2032 年將達到 242.2 億美元，2025 年至 2032 年的年複合成長率為 5.7%。
| 分析範圍 | 分析詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 市場規模（2025年） | 164.3億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期內的年複合成長率（2025-2032） | 5.70% | 預計金額（2032年） | 242.2億美元 |
整合酶抑制劑是一類相對較新的抗逆轉錄病毒藥物，用於治療愛滋病毒/愛滋病。整合酶抑制劑透過特異性抑制愛滋病毒整合酶發揮作用，整合酶是愛滋病毒基因組在宿主細胞內複製所必需的逆轉錄病毒酶。整合酶抑制劑阻止愛滋病毒 DNA 整合到受感染細胞的染色體 DNA 中，從而防止新的愛滋病毒粒子增殖。第一代整合酶抑制劑雷替拉韋於 2007 年核准，提供了一種抑制愛滋病毒複製的新作用機制。它在臨床試驗中表現出高效性和良好的耐受性。此後，新一代整合酶抑制劑，如埃替拉韋和多替拉韋，相繼開發和核准。與現有的抗愛滋病毒療法相比，這些藥物具有更好的療效和耐受性。整合酶抑制劑的引入顯著擴展了愛滋病毒管理的治療選擇。整合酶抑制劑主要透過抑制病毒整合酶的活性來阻止病毒DNA整合到宿主細胞DNA中，用於治療愛滋病毒/愛滋病。
市場動態：
全球整合酶抑制劑市場的成長主要得益於全球愛滋病毒/愛滋病負擔的不斷加重、抗逆轉濾病毒治療(ART) 在愛滋病毒治療中的應用日益廣泛、以及隨著新型和改良整合酶抑制劑的推出，產品平臺不斷壯大。愛滋病毒/愛滋病盛行率的上升、藥物研發的進步以及整合酶抑制劑的有效性和安全性是預測期內推動全球整合酶抑制劑市場成長的關鍵因素。已開發國家政府在應用抗逆轉錄病毒療法方面的優惠舉措提供了有利可圖的機會。然而，愛滋病毒抗藥性株的出現和整合酶抑制劑治療的高成本可能會對市場成長產生負面影響。市場的主要企業正致力於長效注射/口服製劑的研究和開發，以提高治療依從性並推動商機。
本報告的主要特點
- 本報告對全球整合酶抑制劑市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率。
- 它還強調了每個細分市場的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 全球整合酶抑制劑市場的主要企業是根據以下參數進行的分析，例如公司概況、產品系列、主要亮點、財務表現和策略。
- 透過本報告的見解，負責人和企業經營團隊可以就未來的產品發布、合作夥伴關係、市場擴張和行銷策略做出明智的決策。
- 「全球整合酶抑制劑市場」報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
- 相關人員可以透過用於分析全球整合酶抑制劑市場的各種策略矩陣來更輕鬆地做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 愛滋病毒/愛滋病的流行、藥物開發以及療效和安全性的進步
- 醫療費用高昂，且擔心副作用和安全性
- 具有改善治療特性的整合酶抑制劑
- 影響分析
- 主要亮點
- 監管情景
- 產品發布/核准
- PEST分析
- 波特五力分析
- 企業合併（M&A）場景
4. 全球整合酶抑制劑市場：COVID-19感染疾病的影響
- COVID-19流行病學
- 供需側分析
- 經濟影響
5. 全球整合酶抑制劑市場（依藥物類型分類）（2020-2032 年）
- 雷替拉韋
- 多替拉韋
- 埃替拉韋
- 比克替拉韋
- 其他（卡博特韋等）
6. 依給藥途徑分類的全球整合酶抑制劑市場（2020-2032）
- 口服
- 靜脈
- 其他
7. 全球整合酶抑制劑市場依通路分類（2020-2032）
- 醫院藥房
- 零售藥局
- 網路藥局
8. 全球整合酶抑制劑市場（按地區）（2020-2032）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 印度
- 中國
- 日本
- 澳洲
- ASEAN
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第9章 競爭態勢
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc
- Janssen Pharmaceuticals, Inc
- Theratechnologies Inc
- Shionogi & Co., Ltd
- Viatris Inc.
第 10 章 章節
- 分析方法
- 關於出版商
Integrase Inhibitors Market is estimated to be valued at USD 16.43 Bn in 2025 and is expected to reach USD 24.22 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 16.43 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.70% | 2032 Value Projection: | USD 24.22 Bn |
Integrase inhibitors are a relatively new class of antiretroviral drugs used for the treatment of HIV/AIDS. They work by specifically inhibiting HIV integrase, a retroviral enzyme that is essential for the replication of HIV's genome in host cells. Integrase inhibitors prevent integration of HIV viral DNA into the chromosomal DNA of the infected cells, thus blocking the propagation of new HIV virions. The first generation integrase inhibitor raltegravir was approved in 2007, offering a novel mechanism of action in suppressing HIV replication. It demonstrated high efficacy and good tolerability in clinical trials. Since then, newer generations of integrase inhibitors like elvitegravir and dolutegravir have been developed and approved. These agents have shown improved effectiveness and tolerability profiles over existing anti-HIV therapies. The introduction of integrase inhibitors has significantly expanded treatment options for HIV management. Integrase Inhibitors are primarily used in the treatment of HIV/AIDS by inhibiting the activity of the viral enzyme called integrase, thereby preventing the integration of the viral DNA into the host cell's DNA.
Market Dynamics:
The global integrase inhibitors market growth is primarily driven by the rising HIV/AIDS disease burden worldwide, increasing adoption of antiretroviral treatment (ART) for HIV, and robust product pipeline with introduction of newer and improved integrase inhibitor drugs. Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety of integrase inhibitors are major factors expected to drive growth of the global integrase inhibitors market during the forecast period. Favorable government initiatives in developed nations regarding coverage of antiretroviral therapy presents lucrative opportunities. However, the market growth can be negatively impacted by the emergence of drug-resistant strains of HIV and high costs of integrase inhibitor therapies. Key market players are engaged in R&D of long-acting injectable/oral formulations to increase adherence to treatment and drive revenue opportunities.
Key features of the study:
- This report provides in-depth analysis of the global integrase inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global integrase inhibitors market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare group, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd., and Viatris Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global integrase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global integrase inhibitors market.
Detailed Segmentation:
- By Drug:
- Raltegravir
- Dolutegravir
- Elvitegravir
- Bictegravir
- Others (Cabotegravir, etc.)
- By Route of Administration:
- Oral
- Intravenous
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Gilead Sciences
- ViiV Healthcare group
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Shionogi & Co., Ltd.
- Viatris Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Integrase Inhibitor, By Drug
- Market Integrase Inhibitor, By Route of Administration
- Market Integrase Inhibitor, By Distribution Channel
- Market Integrase Inhibitor, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety
- High Treatment Costs, Side Effects and Safety Concerns
- Integrase Inhibitors with improved therapeutic profiles.
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Integrase Inhibitors Market, By Drug, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Raltegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Dolutegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Elvitegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Bictegravir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Others (Cabotegravir, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
6. Global Integrase Inhibitors Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
7. Global Integrase Inhibitors Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
8. Global Integrase Inhibitors Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViiV Healthcare group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Theratechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shionogi & Co., Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
